Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Viehbacher joins PureTech board in first post-Sanofi venture |
||||||||||||||||||||||
In his first public move since being ousted as Sanofi CEO, Chris Viehbacher has joined the board of directors at Boston startup factory PureTech Ventures. The firm, which is active in both research and venture capital, boasts a board with industry influentials Robert Langer, John LaMattina and Ben Shapiro. "It is an honor to join this very dynamic and powerful group of both minds and personalities," Viehbacher said in a statement. "PureTech's pipeline of companies is at an exciting inflection point, and I think the talent within the management team and board can achieve great things." During his 6-year tenure at Sanofi ($SNY), Viehbacher led a business transformation and more than $30 billion in acquisitions, most notably of Genzyme. Prior to his Sanofi role, Viehbacher spent 20 years with GlaxoSmithKline ($GSK), ultimately as president of the North American pharmaceutical division. Story | Release
|